PortfoliosLab logoPortfoliosLab logo
DNLI vs. ALMS
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

DNLI vs. ALMS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Denali Therapeutics Inc. (DNLI) and Alumis Inc (ALMS). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

DNLI vs. ALMS - Yearly Performance Comparison


2026 (YTD)20252024
DNLI
Denali Therapeutics Inc.
16.29%-18.99%-12.23%
ALMS
Alumis Inc
125.72%24.17%-40.90%

Fundamentals

EPS

DNLI:

-$2.96

ALMS:

-$2.71

Total Revenue (TTM)

DNLI:

$0.00

ALMS:

$22.12M

Gross Profit (TTM)

DNLI:

$0.00

ALMS:

$21.30M

EBITDA (TTM)

DNLI:

-$544.31M

ALMS:

-$424.43M

Returns By Period

In the year-to-date period, DNLI achieves a 16.29% return, which is significantly lower than ALMS's 125.72% return.


DNLI

1D
6.19%
1M
-9.35%
YTD
16.29%
6M
32.23%
1Y
41.23%
3Y*
-5.90%
5Y*
-19.25%
10Y*

ALMS

1D
9.01%
1M
-25.80%
YTD
125.72%
6M
452.13%
1Y
258.79%
3Y*
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Denali Therapeutics Inc.

Alumis Inc

Often compared with DNLI:
DNLI vs. ATSGDNLI vs. LLY

Return for Risk

DNLI vs. ALMS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DNLI
DNLI Risk / Return Rank: 6464
Overall Rank
DNLI Sharpe Ratio Rank: 6565
Sharpe Ratio Rank
DNLI Sortino Ratio Rank: 6464
Sortino Ratio Rank
DNLI Omega Ratio Rank: 6060
Omega Ratio Rank
DNLI Calmar Ratio Rank: 6868
Calmar Ratio Rank
DNLI Martin Ratio Rank: 6464
Martin Ratio Rank

ALMS
ALMS Risk / Return Rank: 8989
Overall Rank
ALMS Sharpe Ratio Rank: 8989
Sharpe Ratio Rank
ALMS Sortino Ratio Rank: 9393
Sortino Ratio Rank
ALMS Omega Ratio Rank: 9292
Omega Ratio Rank
ALMS Calmar Ratio Rank: 9090
Calmar Ratio Rank
ALMS Martin Ratio Rank: 8181
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DNLI vs. ALMS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Denali Therapeutics Inc. (DNLI) and Alumis Inc (ALMS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


DNLIALMSDifference

Sharpe ratio

Return per unit of total volatility

0.67

1.84

-1.17

Sortino ratio

Return per unit of downside risk

1.34

3.28

-1.93

Omega ratio

Gain probability vs. loss probability

1.16

1.43

-0.27

Calmar ratio

Return relative to maximum drawdown

1.28

4.03

-2.75

Martin ratio

Return relative to average drawdown

2.48

6.31

-3.84

DNLI vs. ALMS - Sharpe Ratio Comparison

The current DNLI Sharpe Ratio is 0.67, which is lower than the ALMS Sharpe Ratio of 1.84. The chart below compares the historical Sharpe Ratios of DNLI and ALMS, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


DNLIALMSDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.67

1.84

-1.17

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.31

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.02

0.28

-0.30

Correlation

The correlation between DNLI and ALMS is 0.21, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

DNLI vs. ALMS - Dividend Comparison

Neither DNLI nor ALMS has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

DNLI vs. ALMS - Drawdown Comparison

The maximum DNLI drawdown since its inception was -87.74%, which is greater than ALMS's maximum drawdown of -78.95%. Use the drawdown chart below to compare losses from any high point for DNLI and ALMS.


Loading graphics...

Drawdown Indicators


DNLIALMSDifference

Max Drawdown

Largest peak-to-trough decline

-87.74%

-78.95%

-8.79%

Max Drawdown (1Y)

Largest decline over 1 year

-23.42%

-72.19%

+48.77%

Max Drawdown (5Y)

Largest decline over 5 years

-85.38%

Current Drawdown

Current decline from peak

-79.48%

-26.52%

-52.96%

Average Drawdown

Average peak-to-trough decline

-50.89%

-39.76%

-11.13%

Ulcer Index

Depth and duration of drawdowns from previous peaks

12.07%

46.03%

-33.96%

Volatility

DNLI vs. ALMS - Volatility Comparison

The current volatility for Denali Therapeutics Inc. (DNLI) is 22.33%, while Alumis Inc (ALMS) has a volatility of 29.29%. This indicates that DNLI experiences smaller price fluctuations and is considered to be less risky than ALMS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


DNLIALMSDifference

Volatility (1M)

Calculated over the trailing 1-month period

22.33%

29.29%

-6.96%

Volatility (6M)

Calculated over the trailing 6-month period

43.63%

89.40%

-45.77%

Volatility (1Y)

Calculated over the trailing 1-year period

61.96%

141.57%

-79.61%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

62.61%

121.37%

-58.76%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

65.46%

121.37%

-55.91%

Financials

DNLI vs. ALMS - Financials Comparison

This section allows you to compare key financial metrics between Denali Therapeutics Inc. and Alumis Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M250.00M300.00MAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober0
2.07M
(DNLI) Total Revenue
(ALMS) Total Revenue
Values in USD except per share items